

Omid Hamid

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6337848/omid-hamid-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

63

papers

35,272

citations

40

h-index

64

g-index

64

ext. papers

41,668

ext. citations

15

avg, IF

6.5

L-index

#	Paper	IF	Citations
63	The "Great Debate" at Immunotherapy Bridge 2021, December 1st-2nd, 2021.. <i>Journal of Translational Medicine</i> , 2022 , 20, 179	8.5	
62	Longitudinal SARS-CoV-2 mRNA vaccine-induced humoral immune responses in cancer patients. <i>Cancer Research</i> , 2021 ,	10.1	5
61	A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic Cancers. <i>Clinical Cancer Research</i> , 2021 ,	12.9	7
60	Letter Regarding Editorial by Samuel Zagarella. <i>American Journal of Dermatopathology</i> , 2021 , 43, 539-540.	0.9	1
59	Quantitative metastatic lymph node burden and survival in Merkel cell carcinoma. <i>Journal of the American Academy of Dermatology</i> , 2021 , 84, 312-320	4.5	5
58	Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma. <i>European Journal of Cancer</i> , 2021 , 144, 182-191	7.5	23
57	Improved survival in women versus men with merkel cell carcinoma. <i>Journal of the American Academy of Dermatology</i> , 2021 , 84, 321-329	4.5	8
56	Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2656-2666	2.2	35
55	Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. <i>New England Journal of Medicine</i> , 2021 , 385, 1196-1206	59.2	63
54	Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006. <i>European Journal of Cancer</i> , 2021 , 157, 391-402	7.5	2
53	Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab-Response. <i>Clinical Cancer Research</i> , 2020 , 26, 2436	12.9	1
52	Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era. <i>Clinical Cancer Research</i> , 2020 , 26, 4201-4205	12.9	25
51	Mogamulizumab in Combination with Durvalumab or Tremelimumab in Patients with Advanced Solid Tumors: A Phase I Study. <i>Clinical Cancer Research</i> , 2020 , 26, 4531-4541	12.9	21
50	Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials. <i>JAMA Oncology</i> , 2020 , 6, 1256-1264	12.4	27
49	P865 Safety & efficacy of lifileucel (LN-144) tumor infiltrating lymphocyte therapy in metastatic melanoma patients after progression on multiple therapies Independent review committee data update 2020 , 8, A12-A12		2
48	Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2020 , 26, 5869-5878	12.9	50
47	The association between facility volume and overall survival in patients with Merkel cell carcinoma. <i>Journal of Surgical Oncology</i> , 2020 , 122, 254-262	2.8	4

46	Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab. <i>Clinical Cancer Research</i> , 2019 , 25, 6061-6072	12.9	33
45	Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial. <i>European Journal of Cancer</i> , 2019 , 119, 1-10	7.5	79
44	Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. <i>Lancet Oncology</i> , 2019 , 20, 1239-1251	21.7	425
43	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. <i>Lancet Oncology</i> , 2019 , 20, e378-e389	21.7	88
42	Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for -Mutant Melanoma. <i>Cancers</i> , 2019 , 11,	6.6	24
41	Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab. <i>Clinical Cancer Research</i> , 2018 , 24, 4960-4967	12.9	142
40	Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. <i>New England Journal of Medicine</i> , 2018 , 379, 722-730	59.2	659
39	5-year survival outcomes in patients (pts) with advanced melanoma treated with pembrolizumab (pembro) in KEYNOTE-001.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9516-9516	2.2	24
38	Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib. <i>Journal of Clinical Oncology</i> , 2018 , 36, 667-673	2.2	138
37	Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006. <i>British Journal of Cancer</i> , 2018 , 119, 670-674	8.7	60
36	Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer. <i>Cancer Immunology, Immunotherapy</i> , 2017 , 66, 1249-1264	7.4	41
35	Pulse Dose Erlotinib and Zuckerguss Improvement in EGFR-Mutant NSCLC. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 1857-1858	8.9	
34	Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). <i>Lancet</i> , 2017 , 390, 1853-1862	40	703
33	Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. <i>European Journal of Cancer</i> , 2017 , 86, 37-45	7.5	106
32	Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3119-25	2.2	601
31	Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. <i>Journal of Clinical Oncology</i> , 2016 , 34, 871-8	2.2	206
30	Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1510-7	2.2	509
29	Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study. <i>Journal of Clinical Oncology</i> , 2016 , 34, 833-42	2.2	420

28	Pembrolizumab versus ipilimumab for advanced melanoma: Final overall survival analysis of KEYNOTE-006.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9504-9504	2.2	32
27	Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. <i>JAMA - Journal of the American Medical Association</i> , 2016 , 315, 1600-9	27.4	666
26	Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma. <i>European Journal of Cancer</i> , 2016 , 67, 46-54	7.5	54
25	Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. <i>New England Journal of Medicine</i> , 2016 , 375, 1845-1855	59.2	870
24	Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. <i>Lancet Oncology</i> , 2015 , 16, 908-18	21.7	1151
23	Pembrolizumab for the treatment of non-small-cell lung cancer. <i>New England Journal of Medicine</i> , 2015 , 372, 2018-28	59.2	3943
22	Pembrolizumab versus Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2015 , 372, 2521-32	59.2	3792
21	Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1889-94	2.2	1425
20	Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , 2015 , 16, 522-30	21.7	842
19	Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4023-31	2.2	315
18	Survival, safety, and response patterns in a phase 1b multicenter trial of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 9063-9063	2.2	22
17	Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3697-704	2.2	158
16	Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. <i>Lancet</i> , 2014 , 384, 1109-17	40	1340
15	Clinical Benefit from Ipilimumab Therapy in Melanoma Patients may be Associated with Serum CTLA4 Levels. <i>Frontiers in Oncology</i> , 2014 , 4, 110	5.3	33
14	Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. <i>Nature</i> , 2014 , 515, 563-7	50.4	3354
13	Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy. <i>Expert Opinion on Biological Therapy</i> , 2013 , 13, 847-61	5.4	96
12	Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. <i>New England Journal of Medicine</i> , 2013 , 369, 134-44	59.2	2661
11	Sunitinib therapy for melanoma patients with KIT mutations. <i>Clinical Cancer Research</i> , 2012 , 18, 1457-63	12.9	158

10	Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. <i>New England Journal of Medicine</i> , 2012 , 366, 2455-65	59.2	5527
9	Mucosal melanoma: pathogenesis, clinical behavior, and management. <i>Current Oncology Reports</i> , 2012 , 14, 441-8	6.3	93
8	An immune-active tumor microenvironment favors clinical response to ipilimumab. <i>Cancer Immunology, Immunotherapy</i> , 2012 , 61, 1019-31	7.4	562
7	Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab. <i>Cancer Immunology, Immunotherapy</i> , 2012 , 61, 733-7	7.4	71
6	Ipilimumab (IPI) in metastatic castrate-resistant prostate cancer (mCRPC): Results from an open-label, multicenter phase I/II study.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 25-25	2.2	9
5	A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. <i>Journal of Translational Medicine</i> , 2011 , 9, 204	8.5	412
4	Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials. <i>Cancer Immunity</i> , 2010 , 10, 9		78
3	A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. <i>Clinical Cancer Research</i> , 2009 , 15, 5591-8	12.9	457
2	Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. <i>Clinical Cancer Research</i> , 2009 , 15, 7412-20	12.9	2380
1	Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. <i>Cancer</i> , 2007 , 110, 2614-27	6.4	231